BioWorld MedTech

Oct. 28, 2010

View Archived Issues

Low-cost ultrasound disrupts high-priced chemotherapy

PARIS – A four-minute ultrasound exam can determine in the first 30 days of treatment whether troublesome and often brutally expensive chemotherapy should be stopped, continued or even enhanced. (Medical Device Daily) Read More

Device companies anticipate growth, despite challenges

Read More

Elekta's Symmetry now gives 4-D view of moving tumors

Read More

Washington roundup: FDA warning takes aim at another PACS systems firm

Read More

Deals roundup: BSX completes Asthmatx acquisition for $193.5M

Read More

MDD's food for med-tech thought

Read More

Financings roundup: Pacific Biosciences to raise $200M in IPO at $16 a share

Read More

HIT roundup: NY aims for country's largest EMR network

Read More

Agreements/contracts: Myriad, Abbott to assess BRCA mutation testing

Read More

Product Briefs

Read More

MDD's Ortho Extra

Read More